UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

Vanda Pharmaceuticals’ shares were down more than 10% at $4.45 pre-market today, as the company provided an unfavorable ...

Roche today released positive top-line results of the Phase III CENTERSTONE study of Xofluza (baloxavir marboxil), an ...

Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as ...

US CDMO BioCentriq has appointed Syed Husain as its new CEO. Husain, who brings over 20 years of experience in CDMO ...

Applied Therapeutics’ stock surged after the FDA canceled a planned Advisory Committee meeting for govorestat, a treatment ...

Upstream Bio has filed for an IPO on Nasdaq under the symbol "UPB," following recent biotech listings. The company focuses on ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...

Denmark-based Bavarian Nordic and Gavi, the Vaccine Alliance yesterday announced an advance purchase agreement (APA) to ...

GC Therapeutics (GCTx) has launched with the promise to scale and unlock the next generation of cell therapy. GCTx’s induced ...

US companies Incyte and Syndax Pharmaceuticals today announced results from the pivotal Phase II AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients ...